113 related articles for article (PubMed ID: 37919101)
1. Leveraging a Genomic Instability-Derived Signature to Predict the Prognosis and Therapy Sensitivity of Clear Cell Renal Cell Carcinoma.
Wei C; Tao T; Zhou J; Zhu X
Clin Genitourin Cancer; 2024 Apr; 22(2):134-148.e8. PubMed ID: 37919101
[TBL] [Abstract][Full Text] [Related]
2. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma.
Lin H; Qu L; Chen G; Zhang C; Lu L; Chen Y
Eur J Med Res; 2023 Jul; 28(1):236. PubMed ID: 37452355
[TBL] [Abstract][Full Text] [Related]
4. Construction and validation of a model based on immunogenic cell death-associated lncRNAs to predict prognosis and direct therapy for kidney renal clear cell carcinoma.
Cai C; Shu K; Chen W; Ding J; Guo Z; Wei Y; Zhang W
Aging (Albany NY); 2023 Jun; 15(12):5304-5338. PubMed ID: 37379129
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
6. A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma.
Wu S; Li X
Bioengineered; 2021 Dec; 12(1):1642-1662. PubMed ID: 33955826
[TBL] [Abstract][Full Text] [Related]
7. Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Jun; 36(6):e24409. PubMed ID: 35441741
[TBL] [Abstract][Full Text] [Related]
8. Disulfideptosis-associated lncRNAs reveal features of prognostic, immune escape, tumor mutation, and tumor malignant progression in renal clear cell carcinoma.
Li X; Deng X; Liu T; Zhang W; Tao J
Aging (Albany NY); 2024 Feb; 16(4):3280-3301. PubMed ID: 38334964
[TBL] [Abstract][Full Text] [Related]
9. Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Zhang H; Ning Z; Wang B; Liu Y; Tao B; Zhang G; Liu H; Wang C
Dis Markers; 2023; 2023():7219794. PubMed ID: 36741910
[TBL] [Abstract][Full Text] [Related]
10. The vasculogenic mimicry related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma.
Gu Y; Huang Q; Wang Y; Wang H; Xiang Z; Xu Y; Wang X; Liu W; Wang A
BMC Cancer; 2024 Apr; 24(1):420. PubMed ID: 38580922
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma.
Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X
Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983
[TBL] [Abstract][Full Text] [Related]
12. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
[TBL] [Abstract][Full Text] [Related]
13. Identifying the role of transient receptor potential channels (TRPs) in kidney renal clear cell carcinoma and their potential therapeutic significances using genomic and transcriptome analyses.
Ren J; Yuan Q; Liu J; Zhong L; Li H; Wu G; Chen F; Tang Q
BMC Med Genomics; 2022 Jul; 15(1):156. PubMed ID: 35831825
[TBL] [Abstract][Full Text] [Related]
14. Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.
Gui Z; Du J; Wu N; Shen N; Yang Z; Yang H; Wang X; Zhao N; Zeng Z; Wei R; Ma W; Wang C
BMC Cancer; 2023 Jul; 23(1):649. PubMed ID: 37438709
[TBL] [Abstract][Full Text] [Related]
15. Selection of M7G-related lncRNAs in kidney renal clear cell carcinoma and their putative diagnostic and prognostic role.
Zhong S; Chen S; Lin H; Luo Y; He J
BMC Urol; 2023 Nov; 23(1):186. PubMed ID: 37968670
[TBL] [Abstract][Full Text] [Related]
16. Genome instability-related long non-coding RNA in clear renal cell carcinoma determined using computational biology.
Wang Y; Yan K; Wang L; Bi J
BMC Cancer; 2021 Jun; 21(1):727. PubMed ID: 34167490
[TBL] [Abstract][Full Text] [Related]
17. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
Tai R; Leng J; Li W; Wu Y; Yang J
BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
[TBL] [Abstract][Full Text] [Related]
18. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
19. A computational prognostic model of lncRNA signature for clear cell renal cell carcinoma with genome instability.
Cui T; Guo J; Sun Z
Expert Rev Mol Diagn; 2022 Feb; 22(2):213-222. PubMed ID: 34871123
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
